Soligenix Inc
NASDAQ:SNGX
Net Margin
Soligenix Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Soligenix Inc
NASDAQ:SNGX
|
4.2m USD |
-416 870%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.1B USD |
7%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
129.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Soligenix Inc
Glance View
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The firm operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The firm's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Soligenix Inc's most recent financial statements, the company has Net Margin of -416 869.6%.
You don't have any saved screeners yet